Abstracts Archive - Page 1115 of 2425 - ACR Meeting Abstracts

Abstract Number: 1656 • 2018 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis Relevant for Diagnosing Axial Spondyloarthritis Once HLA-B27 Status Is Known? Data from the ASAS, DESIR, and SPACE Cohorts
Miranda van Lunteren¹, Désirée van der Heijde¹, Alexandre Sepriano^1,2, Inger Berg³, Maxime Dougados^4,5, Laure Gossec^6,7, Lennart Jacobsson⁸, Roberta Ramonda⁹, Martin Rudwaleit^10,11, Joachim Sieper^11,12, Robert B.M. Landewé^13,14 and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁵Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Rheumatology, Sorbonne Université, Paris, France, ⁷Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ⁸Rheumatology, University of Gothenburg, Gothenburg, Sweden, ⁹Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ¹⁰Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ¹¹Rheumatology, Charité Campus Benjamin Franklin, Berlin, Germany, ¹²German Rheumatism Research Centre, Berlin, Germany, ¹³Rheumatology, Zuyderland Hospital, Heerlen, Netherlands, ¹⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: A positive family history (PFH) of spondyloarthritis (SpA), in particular a PFH of ankylosing spondylitis (AS) or acute anterior uveitis (AAU), can be used…
Abstract Number: 1657 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Philip Helliwell¹, Alice B Gottlieb², Atul A. Deodhar³, Wolf-Henning Boehncke⁴, Dennis McGonagle¹, Xie L. Xu⁵, Stephen Xu⁵, Yuhua Wang⁵, Elizabeth C Hsia^5,6, Chetan S Karyekar⁵ and Philip J. Mease⁷, ¹U of Leeds, Leeds, United Kingdom, ²NY Medical College, Metropolitan Hospital, NY, NY, ³Oregon Health & Science U, Portland, OR, ⁴U of Geneva, Geneva, Switzerland, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶U Penn School of Medicine, Phila, PA, ⁷Swedish Medical Center & U of Wash, Seattle, WA
Background/Purpose: In a Phase 2 study, Guselkumab (GUS) was shown to be safe & effective in pts w/active PsA w/meaningful improvements in enthesitis. To evaluate…
Abstract Number: 1658 • 2018 ACR/ARHP Annual Meeting
Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?
Imke Redeker¹, Johanna Callhoff¹, Falk Hoffmann², Hildrun Haibel³, Joachim Sieper⁴, Angela Zink⁵ and Denis Poddubnyy⁴, ¹Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany, ²Department of Health Services Research, Carl von Ossietzky University, Oldenburg, Germany, ³Charité Universitätmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: The interval from symptom onset till diagnosis in axial spondyloarthritis (axSpA) was reported a decade ago to be between five and ten years. The…
Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Roy Fleischmann¹, Vinod Chandran², Eric Lespessailles³, Julie Birt⁴, Olivier Benichou⁴, Janelle Erickson⁴ and Catherine Shuler⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Krembil Research Institute and University of Toronto, Toronto, ON, Canada, ³University of Orléans, Orléans, France, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
Abstract Number: 1660 • 2018 ACR/ARHP Annual Meeting
Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
Surjeet Dheer¹, Vivekanand Tiwari², Ammarah Hussain¹, Kakageldi Hommadov¹, Ana Maheshwari¹ and Martin J. Bergman³, ¹Mercy Catholic Medical Center, Philadelphia, PA, ²St John's Hospital, Springfield, IL, ³Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Depression has been shown to be more common in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), than in the general population. The…
Abstract Number: 1661 • 2018 ACR/ARHP Annual Meeting
Factors That May be Associated with Uveitis in Patients with Spondyloarthritis
Timucin Kasifoglu¹, Nazife Sule Yasar Bilge², Sedat Kiraz³, Ihsan Ertenli⁴, Orhan Kucuksahin⁵, Ediz Dalkiliç⁶, Cemal Bes⁷, Nilufer Alpay Kanitez⁸, Pamir Atagunduz⁹, Belkıs Nihan Coşkun¹⁰, Burcu Yagız¹¹, Suleyman Serdar Koca¹², Muhammed Cinar¹³, Aşkın Ateş¹⁴, Servet Akar¹⁵, Onay Gercik¹⁶, Duygu Ersozlu Bakirli¹⁷, Veli Yazisiz¹⁸, Gezmis Kimyon¹⁹, Muge Aydin Tufan²⁰, Hakan Emmungil²¹, Rıdvan Mercan²², Erdal Bodakci²³, Burak Oz²⁴, Zeynel Abidin Akar²⁵, Omer Karadag³, Bahar Kelesoglu²⁶, Sedat Yılmaz²⁷, Ufuk Ilgen²⁸, Yavuz Pehlivan²⁹, Ender Terzioglu³⁰, Levent Kilic⁴, Sukran Erten³¹, Koray Tascilar³² and Umut Kalyoncu³³, ¹Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ²Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ³Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁷Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁸Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ¹⁰Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ¹¹Uludag University, Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, ¹²Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹³GATA, Ankara, Turkey, ¹⁴Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey, ¹⁵Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁶Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹⁷PsART study group, Adana, Turkey, ¹⁸Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²⁰Rheumatology, Cukurova University School of Medicine, Adana, Turkey, ²¹Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ²²PsART study group, Tekirdag, Turkey, ²³Eskisehir Osmangazi University, Eskisehir, Turkey, ²⁴Fırat University, Elazıg, Turkey, ²⁵Frat University, Elazıg, Turkey, ²⁶Rheumatology, Ankara University, Ankara, Turkey, ²⁷Rheumatology Division, Gülhane Training and Research Hospital, Ankara, Turkey, ²⁸Rheumatology, Trakya University, Edirne, Turkey, ²⁹Bursa Uludag University, Bursa, Turkey, ³⁰Rheumatology, Akdeniz University, Antalya, Turkey, ³¹PsART study group, Ankara, Turkey, ³²Numune Research and Teaching Hospital, Ankara, Turkey, ³³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Factors That May Be Associated With Uveitis In Patients With SpondyloarthritisBackground/Purpose: It is known that uveitis is present in the extra-articular findings of spondyloarthritis (SPA)…
Abstract Number: 1662 • 2018 ACR/ARHP Annual Meeting
Interplay Among Inflammation, Adipokines and Endothelial Dysfunction in Patients with Psoriatic Arthritis. Relationship with Cardiovascular and Metabolic Comorbidities. Modulation By Apremilast
Nuria Barbarroja¹, Ivan Arias de la Rosa², Maria Dolores de la Rosa-Garrido³, Carlos Perez-Sanchez¹, Maria Carmen Abalos-Aguilera², Miriam Ruiz-Ponce³, Yolanda Jiménez-Gómez¹, Alejandro Escudero-Contreras², Eduardo Collantes-Estévez¹, Chary Lopez-Pedrera¹ and Maria Dolores Lopez Montilla³, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: 1) To evaluate the association of inflammation, adipokines and endothelial dysfunction with the cardiovascular risk profile and the metabolic comorbidities associated with psoriatic arthritis…
Abstract Number: 1663 • 2018 ACR/ARHP Annual Meeting
Correlation between Biologics and Bath Ankylosing Spondylitis Metrology Index within the First 12 Months of Treatment in Patients with Axial Spondyloarthritis
Clare Longton¹, Marco Massarotti² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Several studies demonstrate efficacy of biologics on disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritides…
Abstract Number: 1664 • 2018 ACR/ARHP Annual Meeting
Fatigue Measurements in Systemic Lupus Erythematosus
Ariane Barbacki¹, Michelle Petri², J. Antonio Avina-Zubieta³, Graciela S. Alarcón⁴ and Sasha Bernatsky⁵, ¹McGill University, Montreal, QC, Canada, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Fatigue is one of the most frequent and disabling issues in systemic lupus erythematosus (SLE). It is, however, difficult to quantify. The Ad Hoc…
Abstract Number: 1665 • 2018 ACR/ARHP Annual Meeting
Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
Daniel Toro¹, Jordi Martorell-Marugán², Daniel Goldman³, Michelle Petri⁴, Pedro Carmona Sanz⁵ and Marta Alarcón-Riquelme^6,7, ¹Bioinformatics and Medical Genomics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Ganada, Spain, ²Bioinformatics Unit, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁶Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain
Background/Purpose: The highly heterogeneous clinical presentation of lupus is characterized by the unpredictable appearance of flares of disease activity and important organ damage. Attempts to…
Abstract Number: 1666 • 2018 ACR/ARHP Annual Meeting
The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Jennifer Rogers¹, Amanda M. Eudy², Lisa Criscione-Schreiber², David Pisetsky³, Kai Sun⁴, Jay Doss⁴ and Megan E. B. Clowse², ¹Medicine, Divison of Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Duke University, Durham, NC, ⁴Division of Rheumatology & Immunology, Duke University, Durham, NC
Background/Purpose: Patient-reported outcome measures (PROs) in SLE can capture patient specific information and the patient perspective, but clinical use can be challenging due to confounding…
Abstract Number: 1667 • 2018 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Approximately 38% of adults living with Systemic Lupus Erythematosus (SLE) experience cognitive impairment (CI) that can detrimentally affect employment, disease self-management, and quality of…
Abstract Number: 1668 • 2018 ACR/ARHP Annual Meeting
Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus
Alexandra Legge¹, Susan Kirkland², Kenneth Rockwood³, Pantelis Andreou², Sang-Cheol Bae⁴, Caroline Gordon⁵, Juanita Romero-Díaz⁶, Jorge Sanchez-Guerrero⁷, Daniel J. Wallace⁸, Sasha Bernatsky⁹, Ann E. Clarke¹⁰, Joan T. Merrill¹¹, Ellen M. Ginzler¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, Murray Urowitz⁷, Ian N. Bruce¹⁵, David A. Isenberg¹⁶, Anisur Rahman¹⁷, Graciela S. Alarcón¹⁸, Michelle Petri¹⁹, Munther A Khamashta²⁰, Mary Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Kristján Steinsson²⁴, Asad A Zoma²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanc²⁹, Ronald F van Vollenhoven³⁰, Andreas Jönsen³¹, Ola Nived³¹, Manuel Ramos-Casals³², Diane L. Kamen³³, Kenneth C. Kalunian³⁴, Søren Jacobsen³⁵, Christine A. Peschken³⁶, Anca Askanase³⁷ and John G. Hanly³⁸, ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Department of Community Health & Epidemiology, Dalhousie University, Halifax, NS, Canada, ³Department of Medicine, Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁷University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁸Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹²Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹³Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁶University College London, London, United Kingdom, ¹⁷Rayne Institute, University College London, London, United Kingdom, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²²FSM, Northwestern University, Chicago, IL, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁵Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²⁶The Feinstein Institute for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ²⁸Emory University School of Medicine, Atlanta, GA, ²⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁰Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ³¹Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ³²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁵Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁶RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Clinical outcomes in SLE are challenging to predict. In non-SLE populations, susceptibility to adverse outcomes has been measured using a frailty index (FI), which…
Abstract Number: 1669 • 2018 ACR/ARHP Annual Meeting
iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites
Deepali Sen¹, Vibeke Strand², Nancy Mathis³, Qiang Fu⁴ and Alfred Kim⁵, ¹Rheumatology, Washington University School of Medicine, St. Louis, MO, ²Stanford University School of Medicine, Palo Alto, CA, ³Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Epidemiology and Biostatistics, Saint Louis University College for Public Health and Social Justice, Saint Louis, MO, ⁵Medicine/Rheumatology, Washington University School of Medicine, St. Louis, MO
iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared with WhitesBackground/Purpose: Complement activation is a hallmark of systemic lupus erythematosus (SLE) pathophysiology.…
Abstract Number: 1670 • 2018 ACR/ARHP Annual Meeting
Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes
Konstantinos Tselios, Dafna D Gladman, Zahi Touma, Jiandong Su, Nicole Anderson and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous studies have described three patterns of disease activity over time in systemic lupus erythematosus (SLE), namely long quiescence, relapsing remitting, and persistently active.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].